-
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
Share
- Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)
- Richard Malamut, Chief Medical Officer at Medincell comments: “Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.”
Contacts
David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86
Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023
Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94
Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94
Medincell
More News From Medincell
Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 9, 2025 to present the half-year financial results (April 2025-September 2025) > Meeting in French, 6:00 pm (CET): https://www.medincell.com/fr/live-fr/ > Meeting in English, 7:00 pm (CET): https://www.medincell.com/live-en/ Shareholders are invited to send their questions to communication@medincell.com, or through the chat system during the videoconference. About...
Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Christophe Douat, Chief Executive Officer, Dr. Richard Malamut, Chief Medical Officer, and Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will participate at the following conferences in December: 8th Annual Evercore Healthcare Conference (Miami, Dec. 2-4) Fireside chat on Wednesday, December 3, 2025, at 9:35am ET (3:35pm CET) Live webcast and replay: https://wsw.com/webcast/evercore52/medcl/2521706 Piper Sandl...
Medincell Awarded New Grant to Fight Malaria
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Quiterie de Beauregard, Head of Global Health at Medincell, said: “On top of previous studies, our program is now backed by a recent large-scale human field study which has shown that oral ivermectin can significantly reduce malaria transmission - by about 26% - during mass drug administration campaigns by neutralizing disease-vector mosquitoes.2 However, the study also highlighted substantial logistical challenges...
